Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-label, Single Dose, Mass Balance Study to Evaluate the Pharmacokinetics, Biotransformation and Excretion of 14C-JTZ-951 in Male Subjects With End-stage Renal Disease Receiving Hemodialysis
Conditions
Interventions
JTZ-951, 14C-JTZ-951
Locations
1
United States
Minneapolis, Minnesota, United States
Start Date
June 1, 2016
Primary Completion Date
September 1, 2016
Completion Date
September 1, 2016
Last Updated
November 29, 2016
NCT05515367
NCT05082584
NCT06352138
NCT06556134
NCT05900635
NCT04667533
Lead Sponsor
Akros Pharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions